NCT05100017View on ClinicalTrials.gov

Methocarbamol vs Oxybutynin for Management of Pain and Discomfort S/P Ureteroscopy Procedure

NARecruitingINTERVENTIONAL
Enrollment

126

Participants

Timeline

Start Date

September 30, 2021

Primary Completion Date

June 30, 2025

Study Completion Date

December 31, 2025

Conditions
Kidney CalculiKidney DiseasesNephrolithiasisUrolithiasisUreteral DiseasesUreteral Calculi
Interventions
DRUG

Methocarbamol

Patients will receive oral Methocarbamol 750mg every six hours as needed for pain post ureteroscopy in addition to the standard postoperative pain regimen.

DRUG

Oxybutynin

Patients will receive oral Oxybutynin XL 10mg daily for pain post ureteroscopy in addition to the standard postoperative pain regimen.

Trial Locations (1)

60611

RECRUITING

Northwestern University, Chicago

All Listed Sponsors
lead

Northwestern University

OTHER